摘要
An accumulation of previous work has established organoids as good preclinical models of human tumors,facilitating translation from basic research to clinical practice.They are changing the paradigm of preclinical cancer research because they can recapitulate the heterogeneity and pathophysiology of human cancers and more closely approximate the complex tissue environment and structure found in clinical tumors than in vitro cell lines and animal models.However,the potential applications of cancer organoids remain to be comprehensively summarized.In the review,we firstly describe what is currently known about cancer organoid culture and then discuss in depth the basic mechanisms,including tumorigenesis and tumor metastasis,and describe recent advances in patient-derived tumor organoids(PDOs)for drug screening and immunological studies.Finally,the present challenges faced by organoid technology in clinical practice and its prospects are discussed.This review highlights that organoids may offer a novel therapeutic strategy for cancer research.
基金
supported by grants from the Project Nn10 of Harbin Medical University Cancer Hospital,Heilongjiang,China(No.Nn102017-02)
the National Natural Science Foundation of China(No.81972706,81872149,82173235,82072904,82103325)
Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation,Heilongjiang,China(No.YQ2019H027)
Distinguished Young Scholars of Harbin Medical University Cancer Hospital,Heilongjiang,China(No.JCQN2018-03)
Yong Elite Training Foundation Grant of Harbin Medical University Cancer Hospital,Heilongjiang,China(No.JY2016-02)
Haiyan Fund Project of Harbin Medical University Cancer Hospital,Heilongjiang,China(No.JJMS 2022-17).